Gouws Capital LLC Eli Lilly & CO Transaction History

Gouws Capital LLC

$140 Million
Q2 2024

A detailed history of Gouws Capital LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Gouws Capital LLC holds 17,723 shares of LLY stock, worth $16.4 Million. This represents 11.48% of its overall portfolio holdings.

Number of Shares

17,723

Previous 18,338 3.35%

Holding current value

$16.4 Million

Previous $14.3 Million 12.48%

% of portfolio

11.48%

Previous 10.82%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	SELL	$724.87 - $909.04 $445,795 - $559,059	-615 Reduced 3.35%	17,723 $16 Million
Q1 2024 May 08, 2024	SELL	$592.2 - $792.28 $802,431 - $1.07 Million	-1,355 Reduced 6.88%	18,338 $14.3 Million
Q4 2023 Jan 24, 2024	SELL	$525.19 - $619.13 $519,938 - $612,938	-990 Reduced 4.79%	19,693 $11.5 Million
Q3 2023 Nov 13, 2023	SELL	$434.7 - $599.3 $63,031 - $86,898	-145 Reduced 0.7%	20,683 $11.1 Million
Q2 2023 Aug 03, 2023	SELL	$350.74 - $468.98 $1.23 Million - $1.65 Million	-3,515 Reduced 14.44%	20,828 $9.77 Million
Q1 2023 May 09, 2023	SELL	$310.63 - $364.82 $449,792 - $528,259	-1,448 Reduced 5.61%	24,343 $8.36 Million
Q4 2022 Feb 08, 2023	SELL	$321.55 - $374.67 $187,463 - $218,432	-583 Reduced 2.21%	25,791 $9.44 Million
Q3 2022 Oct 28, 2022	SELL	$296.48 - $337.87 $63,743 - $72,642	-215 Reduced 0.81%	26,374 $8.53 Million
Q2 2022 Jul 28, 2022	SELL	$278.73 - $327.27 $544,917 - $639,812	-1,955 Reduced 6.85%	26,589 $8.62 Million
Q1 2022 Apr 26, 2022	BUY	$234.69 - $291.66 $52,101 - $64,748	222 Added 0.78%	28,544 $8.17 Million
Q4 2021 Feb 03, 2022	BUY	$224.85 - $279.04 $6.37 Million - $7.9 Million	28,322 New	28,322 $7.82 Million

Others Institutions Holding LLY

# of Institutions

3,868

Shares Held

751M

Call Options Held

6.34M

Put Options Held

7.97M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $878B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gouws Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gouws Capital LLC with notifications on news.

Account

Gouws Capital LLC Eli Lilly & CO Transaction History